Han Steutel
About Han Steutel
Han Steutel is the VP & GM and a Board Member at Vfa, with extensive experience in the pharmaceutical industry, previously holding a senior leadership role at Bristol-Myers Squibb.
Current Role at Vfa
Han Steutel serves as a Board Member at Vfa, a position he has held since November 2009. Based in München, Germany, he participates in strategic decisions and helps guide the organization's mission. His role involves advocating for policies that promote health equity and improve patient access to medications through various programs and initiatives.
Past Experience at Bristol-Myers Squibb
Han Steutel previously held a senior leadership role at Bristol-Myers Squibb, where he served as Vice President and General Manager. During his tenure, he focused on the development and implementation of strategic initiatives aimed at enhancing health equity and access to care for underserved patients. His work included promoting health equity through the Bristol Myers Squibb Foundation.
Expertise in Pharmaceutical Industry
With extensive experience in the pharmaceutical industry, Han Steutel has a strong background in biopharmaceuticals. He has engaged in cutting-edge research across multiple therapeutic areas, including oncology, hematology, immunology, cardiovascular disease, and fibrosis. His involvement spans from promoting health equity to optimizing clinical trial designs using advanced data analytics.
Collaboration and Research Initiatives
Han Steutel collaborates with academic institutions and research organizations globally. His efforts aim to accelerate the discovery and development of new therapies. He invests in translational medicine to bridge the gap between laboratory research and patient care, ensuring that advancements in science translate into effective treatments for patients.
Focus on Digital Health Technologies
Han Steutel leads initiatives to leverage digital health technologies to enhance patient care and treatment outcomes. By integrating advanced digital tools, he aims to improve the efficiency of drug development processes and optimize clinical trial designs. This approach helps in delivering more precise and effective therapies for various conditions, including fibrosis.